The diagnosis of CEP was made by clinical, laboratory, and radiologic findings. The patient began prednisone treatment with a starting dose of 40 mg/d, which was gradually tapered off and stopped at the sixth month. The patient responded well to prednisone. However, the disease relapsed 4 weeks after cessation of treatment as revealed by peripheral eosinophilia and radiologic findings, and prednisone treatment was restarted for 2 years with the fixed dose of 10 mg/d. During prolonged treatment, amenorrhea and major depression developed as side effects. Only 3 weeks after cessation of the second treatment, the disease relapsed again and a third prednisone regimen was given. At this point, an anti-IgE agent, omalizumab, 300 mg every 4 weeks, was started. Prednisone was discontinued at the fourth week of the omalizumab treatment. The patient responded well and all clinical, laboratory, and radiologic findings disappeared (Fig 2). At the 15th month of omalizumab treatment, CEP is in complete remission, with all clinical and laboratory findings normal.